JP6856543B2 - ブロモドメイン阻害剤 - Google Patents
ブロモドメイン阻害剤 Download PDFInfo
- Publication number
- JP6856543B2 JP6856543B2 JP2017553414A JP2017553414A JP6856543B2 JP 6856543 B2 JP6856543 B2 JP 6856543B2 JP 2017553414 A JP2017553414 A JP 2017553414A JP 2017553414 A JP2017553414 A JP 2017553414A JP 6856543 B2 JP6856543 B2 JP 6856543B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1c(*)[o]c2c(*)c(*)c(*)c(*=C)c12 Chemical compound *c1c(*)[o]c2c(*)c(*)c(*)c(*=C)c12 0.000 description 11
- CUAFMWVUXOMCBV-UHFFFAOYSA-N Bc(cc1NS(C)(=O)=O)cc([n]2CC3CC3)c1nc2OC Chemical compound Bc(cc1NS(C)(=O)=O)cc([n]2CC3CC3)c1nc2OC CUAFMWVUXOMCBV-UHFFFAOYSA-N 0.000 description 1
- VPIGOULOKWMRKD-UHFFFAOYSA-N C/C=S(/C)\Nc(cc1I)cc2c1[o]c(-c1ccccc1)c2 Chemical compound C/C=S(/C)\Nc(cc1I)cc2c1[o]c(-c1ccccc1)c2 VPIGOULOKWMRKD-UHFFFAOYSA-N 0.000 description 1
- KFOWRTPPLRLZTJ-UHFFFAOYSA-N CC(C)(CC1=C(C=C2C)Br)CN1C2=O Chemical compound CC(C)(CC1=C(C=C2C)Br)CN1C2=O KFOWRTPPLRLZTJ-UHFFFAOYSA-N 0.000 description 1
- NEWJQMZAUJUMFN-UHFFFAOYSA-N CC(C)(CC1=C(C=C2OS(C(F)(F)F)(=O)=O)C(OC)=O)CN1C2=O Chemical compound CC(C)(CC1=C(C=C2OS(C(F)(F)F)(=O)=O)C(OC)=O)CN1C2=O NEWJQMZAUJUMFN-UHFFFAOYSA-N 0.000 description 1
- YHSMMDZHOZMBOI-UHFFFAOYSA-N CC(N1CC2=CCCC=C2)=NC2C1=CC(C(C=C1C)=CN(C)C1=O)=NC2NS=O Chemical compound CC(N1CC2=CCCC=C2)=NC2C1=CC(C(C=C1C)=CN(C)C1=O)=NC2NS=O YHSMMDZHOZMBOI-UHFFFAOYSA-N 0.000 description 1
- GCADSKMWXUKYCI-UHFFFAOYSA-N CC1=CC(c2cc(N(CC3)S(C)(=O)=O)c3cc2OCC2CC2)=CN(C)C1=O Chemical compound CC1=CC(c2cc(N(CC3)S(C)(=O)=O)c3cc2OCC2CC2)=CN(C)C1=O GCADSKMWXUKYCI-UHFFFAOYSA-N 0.000 description 1
- RVHNMXXUOCOCJW-UHFFFAOYSA-N CCS(N1c(cc(C(C=C2C)=CN(C)C2=O)c(OCC2CC2)c2)c2OCC1)(=O)=O Chemical compound CCS(N1c(cc(C(C=C2C)=CN(C)C2=O)c(OCC2CC2)c2)c2OCC1)(=O)=O RVHNMXXUOCOCJW-UHFFFAOYSA-N 0.000 description 1
- IAQZFUGDAMBYAK-UHFFFAOYSA-N CN(C=C(C=C1OC)c2cc(CS(C)(=O)=O)cc3c2[o]c(C2CC2)n3)C1=O Chemical compound CN(C=C(C=C1OC)c2cc(CS(C)(=O)=O)cc3c2[o]c(C2CC2)n3)C1=O IAQZFUGDAMBYAK-UHFFFAOYSA-N 0.000 description 1
- HCGHJQUBUGIUBL-UHFFFAOYSA-N CN(Cc(c1c2)cc(OCC3CC3)c2C(c2c3cccc2)=CN(C)C3=O)S1(=O)=O Chemical compound CN(Cc(c1c2)cc(OCC3CC3)c2C(c2c3cccc2)=CN(C)C3=O)S1(=O)=O HCGHJQUBUGIUBL-UHFFFAOYSA-N 0.000 description 1
- HIXMULHJNNPDMH-UHFFFAOYSA-N COC(c(cc1Br)cc(NC(C2CC2)=O)c1O)=O Chemical compound COC(c(cc1Br)cc(NC(C2CC2)=O)c1O)=O HIXMULHJNNPDMH-UHFFFAOYSA-N 0.000 description 1
- LGHSRAMGJFIEDF-UHFFFAOYSA-N CS(Cc(cc1Br)cc2c1[o]c(C1CC1)n2)(=O)=O Chemical compound CS(Cc(cc1Br)cc2c1[o]c(C1CC1)n2)(=O)=O LGHSRAMGJFIEDF-UHFFFAOYSA-N 0.000 description 1
- SGVFZKNHVOAEPL-UHFFFAOYSA-N Cc([n](Cc1ccccc1)c1cc(Br)c2)nc1c2S(C)(=O)=O Chemical compound Cc([n](Cc1ccccc1)c1cc(Br)c2)nc1c2S(C)(=O)=O SGVFZKNHVOAEPL-UHFFFAOYSA-N 0.000 description 1
- NMUPXRIGHUYVGD-UHFFFAOYSA-N Cc(c(S=O)c1)cc(F)c1Br Chemical compound Cc(c(S=O)c1)cc(F)c1Br NMUPXRIGHUYVGD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148098P | 2015-04-15 | 2015-04-15 | |
| US62/148,098 | 2015-04-15 | ||
| PCT/US2016/027874 WO2016168682A2 (en) | 2015-04-15 | 2016-04-15 | Bromodomain inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511626A JP2018511626A (ja) | 2018-04-26 |
| JP2018511626A5 JP2018511626A5 (enExample) | 2019-05-23 |
| JP6856543B2 true JP6856543B2 (ja) | 2021-04-07 |
Family
ID=57126317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553414A Expired - Fee Related JP6856543B2 (ja) | 2015-04-15 | 2016-04-15 | ブロモドメイン阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9908885B2 (enExample) |
| EP (2) | EP3831383A1 (enExample) |
| JP (1) | JP6856543B2 (enExample) |
| KR (1) | KR20170135938A (enExample) |
| CN (1) | CN107635558A (enExample) |
| AR (1) | AR104259A1 (enExample) |
| AU (1) | AU2016249273B2 (enExample) |
| CA (1) | CA2982588A1 (enExample) |
| CL (1) | CL2017002606A1 (enExample) |
| CO (1) | CO2017011484A2 (enExample) |
| EA (1) | EA201792229A1 (enExample) |
| EC (1) | ECSP17070706A (enExample) |
| ES (1) | ES2868355T3 (enExample) |
| HK (1) | HK1243326A1 (enExample) |
| IL (1) | IL255006A0 (enExample) |
| MX (1) | MX2017013207A (enExample) |
| PE (1) | PE20180258A1 (enExample) |
| PH (1) | PH12017501888A1 (enExample) |
| SG (1) | SG11201708470SA (enExample) |
| TW (1) | TW201643153A (enExample) |
| WO (1) | WO2016168682A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| AU2016305513A1 (en) | 2015-08-11 | 2018-03-08 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| JP6912039B2 (ja) | 2015-08-12 | 2021-07-28 | ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ | 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用 |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN108314680A (zh) * | 2017-01-16 | 2018-07-24 | 凯惠科技发展(上海)有限公司 | 一种含芳环化合物、其制备方法、药物组合物及应用 |
| TW202332436A (zh) | 2017-04-18 | 2023-08-16 | 美商塞爾基因定量細胞研究公司 | 治療用化合物 |
| CN107098844B (zh) * | 2017-05-17 | 2019-07-30 | 许昌学院 | 一种c-5位硝基取代的酰基吲哚啉类化合物的合成方法 |
| MX2020006612A (es) * | 2017-12-20 | 2020-11-09 | Betta Pharmaceuticals Co Ltd | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. |
| JP2021512167A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 障害を治療するための方法及び化合物 |
| CN108516973A (zh) * | 2018-03-30 | 2018-09-11 | 广西师范大学 | 3-苯并噻唑-1-(3-二甲氨基)丙基喹啉-4-酮衍生物及其制备方法和应用 |
| BR112021001019A2 (pt) * | 2018-07-23 | 2021-04-13 | Celgene Quanticel Research, Inc. | Processo para a preparação de inibidor de bromodomínio |
| TWI833819B (zh) | 2018-10-05 | 2024-03-01 | 美商安尼波那生物公司 | 用於治療與apj受體活性相關的病狀的化合物及組成物 |
| AU2019372121A1 (en) | 2018-10-30 | 2021-05-27 | Nuvation Bio Inc. | Heterocyclic compounds as BET inhibitors |
| JP2022523073A (ja) * | 2019-01-29 | 2022-04-21 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| US20230065463A1 (en) * | 2019-01-29 | 2023-03-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160198A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160196A1 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| EP4424379A3 (en) * | 2019-04-24 | 2024-10-30 | Convergene Llc | Small molecule bromodomain inhibitors and uses thereof |
| CN112174945B (zh) * | 2019-07-02 | 2022-06-07 | 四川大学 | 具有抗癌作用的吲唑类化合物及其制备方法和用途 |
| KR102677015B1 (ko) * | 2019-07-02 | 2024-06-19 | 누베이션 바이오 인크. | Bet 억제제로서의 헤테로시클릭 화합물 |
| WO2021022163A2 (en) * | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| IL295101B1 (en) | 2020-01-29 | 2025-10-01 | Foghorn Therapeutics Inc | Materials and their use |
| WO2022025880A1 (en) * | 2020-07-29 | 2022-02-03 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| CN114014842B (zh) * | 2021-11-04 | 2024-03-01 | 中国药科大学 | 一种杂环酮类化合物与其组合物及其制备方法和应用 |
| WO2023090859A1 (ko) * | 2021-11-17 | 2023-05-25 | 일동제약(주) | 아이속사졸 유도체의 제조 방법 및 그의 신규한 중간체 |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1349418A (en) * | 1919-08-05 | 1920-08-10 | George F Flynn | Motor-support |
| US3590036A (en) * | 1968-11-18 | 1971-06-29 | George Y Lesher | Naphthyridine-3-carboxylic acids,their derivatives and preparation thereof |
| DE2011970A1 (en) | 1970-03-13 | 1971-11-18 | CH. Boehringer Sohn, 6507 Ingelheim | Imidazo-(1, 2-a)- pyrimidines prepn |
| US3635667A (en) | 1970-07-23 | 1972-01-18 | Fmc Corp | Drycleaning with hydrogen peroxide |
| GB1322318A (en) * | 1971-05-19 | 1973-07-04 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and esters |
| BE786028A (fr) | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer |
| DE2356005A1 (de) | 1973-11-09 | 1975-05-22 | Boehringer Sohn Ingelheim | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung |
| AU577105B2 (en) | 1985-04-02 | 1988-09-15 | T.P.O. :Pharmachim: | Acylaminic penicillin derivatives |
| US6117940A (en) | 1997-10-17 | 2000-09-12 | Mjalli; Adnan M. M. | Amino-ketone solid support templates |
| KR100904011B1 (ko) * | 2000-06-12 | 2009-06-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물 및 그의 제조 방법 |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| MXPA05002004A (es) | 2002-09-26 | 2005-04-28 | Pfizer | Derivados de pirazol. |
| JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| AU2004276268B2 (en) * | 2003-09-23 | 2009-01-29 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
| WO2005030791A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| KR100703068B1 (ko) | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2005095384A1 (en) | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| KR100781704B1 (ko) | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| JP5049970B2 (ja) | 2005-07-26 | 2012-10-17 | サノフイ | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
| UA93882C2 (ru) | 2005-07-26 | 2011-03-25 | Санофи-Авентис | Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы |
| US20070099911A1 (en) | 2005-10-28 | 2007-05-03 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| US7795262B2 (en) | 2006-03-10 | 2010-09-14 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
| GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
| MY150746A (en) | 2006-12-27 | 2014-02-28 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| WO2008077556A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
| NZ577980A (en) | 2006-12-27 | 2012-01-12 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
| WO2009029214A1 (en) * | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| MX2010008375A (es) | 2008-01-30 | 2011-03-04 | Cephalon Inc Star | Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3). |
| JP5433691B2 (ja) | 2008-06-25 | 2014-03-05 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体 |
| WO2010039186A2 (en) * | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| US8283360B2 (en) * | 2008-12-19 | 2012-10-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic derivatives and methods of use thereof |
| RU2615130C2 (ru) | 2009-10-06 | 2017-04-04 | Милленниум Фармасьютикалз, Инк | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 |
| CA2784710A1 (en) * | 2009-12-15 | 2011-06-23 | Shionogi & Co., Ltd. | Oxadiazole derivative having endothelial lipase inhibitory activity |
| AU2011273931B2 (en) | 2010-06-28 | 2015-04-23 | Merck Patent Gmbh | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| JPWO2012086735A1 (ja) * | 2010-12-22 | 2014-06-05 | 大正製薬株式会社 | 縮合複素環化合物 |
| WO2012162254A1 (en) | 2011-05-23 | 2012-11-29 | Elan Pharmaceuticals, Inc. | Inhibitors of lrrk2 kinase activity |
| RU2477723C2 (ru) * | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| CN103183675A (zh) | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| WO2013130855A1 (en) * | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| TR201807207T4 (tr) * | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| JP2014024838A (ja) * | 2012-06-21 | 2014-02-06 | Taisho Pharmaceutical Co Ltd | 縮合複素環化合物を有効成分として含有する血糖低下作用薬 |
| WO2014015088A1 (en) * | 2012-07-19 | 2014-01-23 | Bristol-Myers Squibb Company | Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| BR112015016580A2 (pt) | 2013-01-11 | 2017-07-11 | Fujifilm Corp | composto heterocíclico contendo nitrogênio ou sal deste |
| AU2014249192B2 (en) * | 2013-03-11 | 2017-12-21 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
| KR102244719B1 (ko) * | 2013-03-15 | 2021-04-26 | 플렉시콘 인코퍼레이티드 | 헤테로시클릭 화합물 및 그의 용도 |
| EA029312B1 (ru) * | 2013-05-27 | 2018-03-30 | Новартис Аг | Производные имидазопирролидинона и их применение при лечении заболеваний |
| WO2015004533A2 (en) * | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| WO2014205594A1 (en) * | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
| HUE040645T2 (hu) * | 2013-06-26 | 2019-03-28 | Abbvie Inc | BTK-inhibitor primer karboxamidok |
| HRP20200341T1 (hr) * | 2013-10-18 | 2020-06-12 | Celgene Quanticel Research, Inc. | Bromodomenski (bet) inhibitori |
| WO2015081189A1 (en) * | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| RU2695664C1 (ru) * | 2013-12-09 | 2019-07-25 | Юсб Байофарма Спрл | Производные имидазопиридина в качестве модуляторов активности tnf |
| WO2015105749A1 (en) * | 2014-01-07 | 2015-07-16 | Bristol-Myers Squibb Company | Sulfone amide linked benzothiazole inhibitors of endothelial lipase |
| US9499551B2 (en) | 2014-01-24 | 2016-11-22 | Confluence Life Sciences, Inc. | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases |
| KR102702503B1 (ko) * | 2014-04-23 | 2024-09-05 | 인사이트 홀딩스 코포레이션 | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| US11319318B2 (en) * | 2015-03-05 | 2022-05-03 | Boehringer Ingelheim International Gmbh | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 |
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
-
2016
- 2016-04-14 AR ARP160101014A patent/AR104259A1/es unknown
- 2016-04-15 SG SG11201708470SA patent/SG11201708470SA/en unknown
- 2016-04-15 US US15/130,503 patent/US9908885B2/en active Active
- 2016-04-15 MX MX2017013207A patent/MX2017013207A/es unknown
- 2016-04-15 AU AU2016249273A patent/AU2016249273B2/en not_active Ceased
- 2016-04-15 KR KR1020177032364A patent/KR20170135938A/ko not_active Withdrawn
- 2016-04-15 EP EP20215944.8A patent/EP3831383A1/en not_active Withdrawn
- 2016-04-15 PE PE2017002197A patent/PE20180258A1/es not_active Application Discontinuation
- 2016-04-15 TW TW105111879A patent/TW201643153A/zh unknown
- 2016-04-15 CN CN201680034663.2A patent/CN107635558A/zh active Pending
- 2016-04-15 EA EA201792229A patent/EA201792229A1/ru unknown
- 2016-04-15 EP EP16780891.4A patent/EP3283077B1/en active Active
- 2016-04-15 WO PCT/US2016/027874 patent/WO2016168682A2/en not_active Ceased
- 2016-04-15 CA CA2982588A patent/CA2982588A1/en active Pending
- 2016-04-15 JP JP2017553414A patent/JP6856543B2/ja not_active Expired - Fee Related
- 2016-04-15 ES ES16780891T patent/ES2868355T3/es active Active
- 2016-04-15 HK HK18102785.5A patent/HK1243326A1/zh unknown
-
2017
- 2017-10-13 CL CL2017002606A patent/CL2017002606A1/es unknown
- 2017-10-15 IL IL255006A patent/IL255006A0/en unknown
- 2017-10-18 PH PH12017501888A patent/PH12017501888A1/en unknown
- 2017-10-24 EC ECIEPI201770706A patent/ECSP17070706A/es unknown
- 2017-11-08 CO CONC2017/0011484A patent/CO2017011484A2/es unknown
-
2018
- 2018-01-12 US US15/870,557 patent/US10494371B2/en active Active
-
2019
- 2019-11-04 US US16/673,839 patent/US10807982B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016168682A3 (en) | 2016-12-08 |
| CL2017002606A1 (es) | 2018-05-18 |
| SG11201708470SA (en) | 2017-11-29 |
| US20200071332A1 (en) | 2020-03-05 |
| PE20180258A1 (es) | 2018-02-05 |
| HK1243326A1 (zh) | 2018-07-13 |
| US20170050968A1 (en) | 2017-02-23 |
| TW201643153A (zh) | 2016-12-16 |
| EP3283077A4 (en) | 2019-01-23 |
| EP3283077A2 (en) | 2018-02-21 |
| CA2982588A1 (en) | 2016-10-20 |
| US10494371B2 (en) | 2019-12-03 |
| ES2868355T3 (es) | 2021-10-21 |
| AU2016249273A1 (en) | 2017-11-09 |
| AU2016249273B2 (en) | 2020-07-09 |
| ECSP17070706A (es) | 2017-12-01 |
| PH12017501888A1 (en) | 2018-03-05 |
| MX2017013207A (es) | 2018-02-19 |
| EP3831383A1 (en) | 2021-06-09 |
| EP3283077B1 (en) | 2021-03-10 |
| AR104259A1 (es) | 2017-07-05 |
| US20180134710A1 (en) | 2018-05-17 |
| WO2016168682A2 (en) | 2016-10-20 |
| US10807982B2 (en) | 2020-10-20 |
| JP2018511626A (ja) | 2018-04-26 |
| IL255006A0 (en) | 2017-12-31 |
| EA201792229A1 (ru) | 2018-05-31 |
| KR20170135938A (ko) | 2017-12-08 |
| CO2017011484A2 (es) | 2018-01-31 |
| US9908885B2 (en) | 2018-03-06 |
| CN107635558A (zh) | 2018-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6856543B2 (ja) | ブロモドメイン阻害剤 | |
| US11884680B2 (en) | Bromodomain inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190409 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190410 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190808 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190809 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210302 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210318 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6856543 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |